DEAR EDITOR, The authors of the British Association of Dermatologists' (BAD) clinical guidelines for managing actinic keratosis 1 and the BAD's Therapy & Guidelines subcommittee wish to notify readers of the 2017 guideline publication that the marketing authorization for ingenol mebutate has been suspended by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), as of 27 January 2020. 2 This is due to emerging evidence 3,4 suggesting possible links between use of the product and an increased risk of developing skin cancers. The manufacturers are recalling all stocks of this medication. 5 Further advice is available at the MHRA website. 6

This is the first large-scale study to attempt to measure the impact of a range of photodermatoses on QoL. Photodermatoses have a major impact on QoL. This impact is highest in AP and PAD.

The contribution of friction to contact dermatitis is under-recognized probably because dermatologists do not think about the potential for physical forces to induce eczematous changes in the skin.